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Abstract: Secondary hyperparathyroidism (SHPT), a very frequent, severe, and worsening 
complication of chronic kidney disease, is characterized by high serum parathyroid hormone 
(PTH), parathyroid gland hyperplasia, and disturbances in mineral metabolism. Clinically, 
SHPT shows renal osteodystrophy, vascular calcification, cardiovascular damage, and fatal 
outcome. Calcium-sensing receptor (CaSR) is the main physiological regulator of PTH secre-
tion; its activation by calcium rapidly inhibits PTH. Another important player in regulating 
mineral metabolism is vitamin D receptor (VDR), which is under the influence of vitamin D and 
influences the intestinal absorption of calcium and phosphate, PTH gene expression, and bone 
calcium mobilization. Serum phosphate levels influence fibroblast growth factor 23 (FGF-23) 
production, a phosphatonin that modulates serum phosphate reabsorption, PTH synthesis, and 
vitamin D production. Current therapeutic approaches consist of 1) phosphate intake control 
by diet or phosphate binders, 2) vitamin D by VDR activation, and 3) calcimimetic agents that 
activate CaSR. Recently, a new long-acting peptide (etelcalcetide) belonging to the calcimimet-
ics class was approved for intravenous use in hemodialysis patients with SHPT. Etelcalcetide 
binds directly to CaSR, by a sulfide bond, inhibiting the production and secretion of PTH by 
parathyroid glands. After intravenous administration in rats, etelcalcetide is quickly distributed 
to the tissues and eliminated by kidneys, while in uremic animals the nonrenal excretion is only 
1.2%. In hemodialysis patients, the treatment itself is the main route of elimination. Etelcalcetide 
in hemodialysis patients with SHPT was more effective than placebo and cinacalcet, with a PTH 
reduction of .30% in 76% of patients with etelcalcetide versus 10% with placebo. Particular 
attention was paid to the safety of the drug; the most common adverse event was asymptomatic 
blood calcium reduction, similar to cinacalcet, while gastrointestinal symptoms were less fre-
quent. This promising new drug available for better control of SHPT will, together with drugs 
already in use, optimize the treatment to normalize the biochemical parameters.
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Pathogenesis of secondary hyperparathyroidism 
in chronic kidney disease
Parathyroid hormone (PTH) is a key regulator of calcium metabolism; it stimulates bone 
reabsorption, increases serum calcium and phosphorus levels, and promotes vitamin D 
synthesis.1 Secondary hyperparathyroidism (SHPT), a common, serious, and progres-
sive complication of chronic kidney disease (CKD), is characterized by high serum 
PTH, parathyroid gland hyperplasia, and disturbances in mineral metabolism, mainly 
hypocalcemia and hyperphosphatemia.1 These mineral disturbances mainly cause renal 
osteodystrophy, progressive vascular calcification, and in turn, cardiovascular disease 
and death, especially in patients receiving hemodialysis.2–5 Together, this constella-
tion of comorbidities is known as CKD–mineral and bone disorder (CKD-MBD).6 
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In the US, the estimated prevalence of SHPT in patients 
with CKD ranges from 2 to nearly 5 million individuals, 
with 30%–50% of end-stage renal disease (ESRD) patients 
affected by SHPT.3
Under normal physiological conditions (Figure 1), 
the principal regulator of PTH secretion and parathyroid 
gland function is the calcium-sensing receptor (CaSR).4–7 
Activation of the CaSR by serum calcium rapidly inhibits 
PTH synthesis and secretion and parathyroid gland growth. 
Furthermore, the CaSR influences PTH gene expression 
and may also upregulate the vitamin D receptor (VDR). 
Parathyroid glands express high levels of the VDR, which 
when activated by vitamin D binding decreases PTH gene 
transcription; on the contrary, decreasing levels of vitamin D 
or vitamin D deficiency stimulate PTH synthesis.8 VDRs are 
expressed in several tissues, such as the intestines (where 
calcium and phosphate absorption is regulated), the kidneys 
(where calcium reabsorption is regulated), and in bone (where 
calcium mobilization is regulated).9 VDR activation by the 
active form of vitamin D, calcitriol, also elevates parathyroid 
expression of the CaSR.4–7 Moreover, VDR activation in 
the gastrointestinal tract increases calcium absorption, thus 
elevating serum calcium levels and controlling parathyroid 
gland activity through CaSR activation.8,10 Serum phosphorus 
and phosphorus intake also affect calcitriol levels, primarily 
through modulation of the activity of 25-hydroxyvitamin 
D
3
-1α-hydroxylase and PTH expression by the parathyroid. 
Phosphate also stimulates production of the phosphatonin 
and fibroblast growth factor 23 (FGF-23) in osteocytes and 
osteoblasts.11 FGF-23 binds to a receptor complex consist-
ing of FGFR1 and the transmembrane protein Klotho and 
modulates phosphate reabsorption, PTH synthesis, and 
vitamin D production. In turn, both PTH and FGF-23 regu-
late phosphate reabsorption by affecting the local density of 
the type 2 sodium-dependent phosphate cotransporter in the 
renal proximal tubules.11,12
Hyperphosphatemia, hypocalcemia, and low calcitriol 
levels that occur as kidney function declines are major play-
ers in the pathogenesis of SHPT in patients with CKD.11,13 
Low calcium levels can downregulate the cellular expres-
sion of CaSR after the parathyroid cell proliferation. 
Compensatory downregulation of the CaSR and the VDR in 
the parathyroid may play a central role in the development 
of mineral disturbances in SHPT.11,13 Hyperphosphatemia 
Figure 1 Regulation of PTH synthesis and secretion by CaSR and vDR in parathyroid glands.
Abbreviations: Ca++, ionized calcium; CaSR, calcium-sensing receptor; PTH, parathyroid hormone; vDR, vitamin D receptor.
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directly causes increased PTH synthesis and secretion, and 
parathyroid hyperplasia, with downregulation of both CaSR 
and VDR expression in SHPT.14 Additionally, high serum 
phosphate levels inhibit the activity of 25-hydroxyvitamin 
D
3
-1α-hydroxylase, the enzyme that converts vitamin D to 
its active form, calcitriol, thus disrupting the feedback loop 
acting through the CaSR and VDR that suppresses PTH.5,11 
Persistent alterations in the signaling of the CaSR and VDR, 
including the reduced expression of both, can eventually 
result in refractory SHPT, in which the parathyroid gland 
becomes insensitive to calcium- or calcitriol-mediated inhi-
bition of PTH synthesis.4,10 As kidney function declines in 
CKD, levels of FGF-23 are also increased.11 This has been 
attributed, at least in part, to reduced levels of Klotho in the 
kidney and parathyroid gland that occur as kidney function 
declines.15,16 Two additional factors that have been associated 
with disease progression and cardiovascular disease in CKD 
are indoxyl sulfate and p-cresyl sulfate, products of colonic 
bacterial fermentation of dietary proteins.17
Continuous stimulation of the parathyroid glands by 
these derangements in mineral homeostasis promotes PTH 
synthesis and eventually parathyroid hyperplasia.11 Because 
of their integral roles in the pathogenesis of SHPT, the CaSR, 
the VDR, and FGF-23 are biologically plausible targets for 
emerging therapies in the treatment of this disorder.
Current treatment options
SHPT is a common, serious, and costly manifestation of 
CKD, with negative effects on patient outcomes, especially 
on HD. With current treatment approaches, a considerable 
proportion of patients have inadequately controlled PTH, 
phosphorus, and/or calcium levels, and the ranges of these 
often fall outside of recommended ranges.18 Data from the 
Dialysis Outcomes and Practice Patterns Study (DOPPS) 
of patients receiving hemodialysis for .180 days support 
a greater risk of cardiovascular and all-cause mortality 
in patients with calcium levels .10 mg/dL, phosphorus 
levels .7 mg/dL, and PTH levels .600 pg/mL; risks are 
likewise increased in patients with combinations of these 
high-risk categories.19,20
Current treatment for SHPT should follow three steps: 
reduction of phosphorus uptake by dietary restriction or the 
use of phosphate binders; control of PTH with the use of 
vitamin D metabolites; and the use of calcimimetics, cur-
rently agents that allosterically modify the CaSR to enhance 
activation in the presence of circulating levels of calcium, 
thus reducing PTH (Table 1).21 Parathyroidectomy is usually 
a treatment strategy of last resort, after pharmacotherapy has 
failed.11 The goal of treatment is to maintain serum calcium, 
serum phosphorus, and PTH within accepted targeted 
ranges.22 Because of the limitations associated with the 
standard-of-care treatment for SHPT, PTH targets are not 
met for many patients.23
Low-phosphorus diet and phosphate 
binders
Current guidelines suggest maintaining serum calcium and 
phosphorous with the normal range via balanced diet and/or 
phosphate binders administration.22 The use of vegetarian 
products as well as protein restriction is commonly sug-
gested to limit phosphate intake.22 Cooking methods such as 
boiling are also proposed to limit (20%–70%) the amount 
of phosphate contained in different foods.23 A recent 
meta-analysis suggested a significant reduction of phos-
phate levels of about 0.8 mg/dL (95% confidence interval 
[CI]: -1.43 to -0.18).24
In spite of these data, phosphate binders have long been 
perceived as a cornerstone in the treatment of SHPT.1 Indeed, 
due to poor treatment adherence, diet is often insufficient 
to reach a desirable control of serum phosphate levels, and 
a wide range of phosphate binders are now available.25 
Although effective, aluminum-based phosphate binders have 
been replaced by calcium and iron-based and polymer-based 
phosphate binders due to their toxicity.25 Current guidelines 
suggest to limit aluminum-based phosphate binders in case 
of severe hyperphosphatemia and for a short period of time.22 
When compared to placebo, all available compounds have 
been shown to lower serum phosphate to similar extent.23 
However, differences among drugs may exist. Calcium-free 
phosphate binders are associated with lower serum calcium, 
and differences in PTH control with various drugs have been 
reported.24 Preliminary data also suggest that phosphate 
restriction and calcium-free phosphate binders may reduce 
FGF-23.25 Although the clinical relevance of different bio-
chemical profiles still needs to be elucidated, some lines of 
evidence suggest that calcium-based phosphate binders may 
accelerate vascular calcification deposition and progres-
sion when compared to calcium-free phosphate binders.26 
Calcium supplements can represent a substantial portion 
of an individual’s daily calcium intake and contribute to 
deposition of calcium crystals in soft tissues26 in individuals 
with normal renal function27 as well as renal function impair-
ment.26 Also, evidence supports the notion that calcium-free 
phosphate binders are associated with a better survival when 
compared to calcium-based phosphate binders,28 although 
future efforts are still required to shed light on this vexing 
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question. Similarly, future studies should investigate the 
impact of combination therapies for CKD-MBD on cal-
cium and phosphate balance and their effect on outcome in 
CKD patients.29
Calcimimetics
Calcimimetics are a newer class of agents for the treatment 
of SHPT in patients receiving renal replacement therapy.30 
This class of agents allosterically bind and activate the CaSR, 
increasing the response of the receptor to serum calcium 
(orthosteric agonist).22 To date, cinacalcet is the only commer-
cially available drug of this class, although other molecules 
are under clinical development or about to hit the market.25,30 
Although effective in PTH lowering, calcimimetics do not 
increase intestinal calcium or phosphate absorption.22,31 In the 
pivotal phase 3 clinical study, treatment of uncontrolled SHPT 
with cinacalcet or placebo for 26 weeks resulted in a greater 
proportion of patients in the calcimimetic arm achieving intact 
PTH levels #250 pg/mL (43% versus 5% in the cinacalcet 
and placebo-treated study arms, respectively).30 Of interest, 
besides a greater overall PTH suppression, a better control of 
serum calcium and phosphorous was also noted.30 Additional 
studies further corroborate the PTH suppression efficacy 
of cinacalcet in combination with vitamin D or vitamin D 
analogs when compared with calcitriol as monotherapy.21 
Sixty five (65%) versus 36% of patients receiving cinacalcet 
or active vitamin D open-label monotherapy experienced 
a reduction in PTH from baseline of at least 30% in the 
ACHIEVE study.32 In another open-label study of 16 weeks, 
71% of patients receiving cinacalcet plus low-dose, active 
vitamin D treatment achieved PTH #300 pg/mL versus 22% 
of patients receiving vitamin D alone.33 Notably, in all these 
studies, mild-to-moderate hypocalcemia was a common, 
albeit easily managed, side effect attributed to CaSR modu-
lation and likely a reduction in calcium mobilization from 
bone due to a tighter PTH control.11 Finally, the EVOLVE 
study, the largest placebo-controlled, double-blind clinical 
trial conducted in dialysis patients with SHPT also confirmed 
a greater achievement of biochemical parameters of CKD-
MBD among patients treated with cinacalcet compared to 
placebo.34,35 Although the primary end point of the study (ie, 
time until death, myocardial infarction, hospitalization for 
unstable angina, heart failure, or peripheral vascular event) 
was unmet, serum levels of intact PTH, calcium, phosphate, 
and FGF-23 were better controlled among patients allocated 
to cinacalcet.16,35 Notably, when compared to placebo, the 
most common complaints associated with treatment with 
calcimimetic were nausea, vomiting, and hypocalcemia 
(12% versus 2% of cinacalcet as opposed to placebo-treated 
patients experiencing hypocalcemia)16,34 that contributed to 
the slightly higher discontinuation rate due to adverse events 
(AEs) reported in the cinacalcet group (16% versus 12%). 
CaSR modulation may exert beneficial effects beyond serum 
biochemical parameters control.36,37 Although inconclusive, 
the ADVANCE study (a phase 4 randomized clinical trial) 
showed a trend toward vascular calcification progression 
attenuation among subjects receiving low doses of active 
vitamin D and cinacalcet versus flexible doses of vitamin D 
to control SHPT.38 Overall, a small but not significant reduc-
tion in coronary artery calcification (CAC) progression was 
noted. However, patients adherent39 to the assigned therapy 
or with higher burden of CAC or cardiac valve calcification 
at study inception seem to benefit more from this combination 
theraphy.37,40 In a post hoc analysis, subjects with aortic valve 
calcification treated with CasR modulators experienced a 74% 
risk reduction (adjusted odds ratio: 0.26; 95% CI: 0.10–0.64) 
of CAC progression.40 As in a previous study, the most com-
mon side effects reported by subjects assigned to cinacalcet 
treatment were gastrointestinal discomfort and hypocalcemia, 
affecting 21% and 7% of patients, respectively.37
Although CaSR modulation is an effective strategy to 
control SHPT, future efforts are needed to elucidate the effect 
interactions of different drugs to control CKD-MBD. In a 
recently published post hoc analysis38 of the INDEPENDENT 
study, a potentially deleterious effect of the combination of 
cinacalcet with calcium containing phosphate binders was 
shown. Indeed, among the 466 incident to dialysis patients 
recruited in the study, sevelamer but not calcium carbonate 
administration was associated with survival benefit.38 
However, the concomitant administration of cinacalcet 
significantly modulated the impact of these phosphate 
binders on mortality (interaction test P=0.006). Coadmin-
istration of cinacalcet and calcium-free phosphate binders 
(hazard ratio: 0.34, 95% CI: 0.14–0.81, P=0.01 for subjects 
treated with sevelamer and receiving cinacalcet or not) but 
not cinacalcet and calcium-containing phosphate binders 
(hazard ratio: 1.28, 95% CI: 0.82–2.00; P=0.26 for subjects 
treated with calcium cinacalcet and receiving cinacalcet or 
not) was associated with improved survival.38 Although the 
hypothesis generating this piece of evidence suggests that 
calcium balance modulation may impact survival in CKD, 
future efforts are needed to explore the effects of different 
combination therapies.
Vitamin D and vitamin D 
derivatives
In patients with CKD stages 3–5 (Table 2), both nutri-
tional (cholecalciferol, ergocalciferol, calcifediol) and 
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VDR activators (VDRAs) such as calcitriol and its analogs 
can improve abnormal mineral homeostasis.22 Although 
the optimal target of 25(OH)D remains uncertain, serum 
levels .30 ng/mL are accepted as a normal threshold.41 
Clinical data support a mild effect of nutritional vitamin D 
against nonsevere SHPT in CKD stages 3–5.42 International 
guidelines suggest the correction of nutritional vitamin D 
deficiency as a first-line therapy to counteract the onset 
and progression of CKD-MBD in predialysis patients.41,43,44 
However, due to the inconsistency of current evidence 
on the best approach to correct 25(OH)D deficiency, the 
KDIGO, NICE, and ERBP guidelines are unable to provide 
any therapeutic suggestion on how to replenish low 25(OH)
D levels.22,41,43 Doses originally recommended by KDOQI 
guidelines were often insufficient to achieve the expected 
25(OH)D levels.45 Higher doses of cholecalciferol and 
ergocalciferol were thus suggested in 2012,46 showing the 
superiority of cholecalciferol compared to ergocalciferol in 
replenishing 25(OH)D deficiency.47 Wetmore et al48 have 
recently randomized 44 nondialysis CKD patients to receive 
cholecalciferol 50,000 IU/wk versus ergocalciferol 50,000 
IU/wk for 12 weeks, without suspending concomitant active 
therapy. Although cholecalciferol was more effective than 
ergocalciferol at raising serum 25(OH)D levels (45±16.5 
ng/mL and 30.7 versus 15.3 ng/mL, P,0.01), changes in 
serum PTH or active vitamin D were similar between the 
groups, and a similar decline of 25(OH)D levels between the 
groups was observed after cessation of therapy.48 Recent data 
support an innovative efficacy of a modified-release formu-
lation of calcifediol,49 probably favored by its capability to 
raise 25(OH)D levels slowly enough for limiting an abrupt 
activation of vitamin D catabolism.50 This novel compound 
was effective in reducing iPTH levels in 44 predialysis CKD 
patients in a dose-dependent manner compared to placebo.49 
Independently from the type and dose of nutritional vitamin D 
adopted, 25(OH)D levels should not exceed 100 ng/mL, 
and particular caution should be paid while supplementing 
patients at high risk of 1-α-hydroxylase activity, as kidney 
transplant patients and those affected by sarcoidosis or B-cell 
lymphoma.42 VDRA was shown to be effective in counteract-
ing SHPT in nondialysis CKD patients.51 Selective VDRAs 
such as paricalcitol and doxercalciferol were developed to 
provide VDR activation with a lower risk of positive Ca and 
P balance.52 In a 12-week, placebo-controlled, randomized 
study in patients receiving dialysis, paricalcitol effectively 
reduced PTH levels, with 6.7% of assessments indicative of 
hypercalcemia (serum calcium .10.5 mg/dL) versus 3.3% 
with placebo.53 Doxercalciferol has also been shown to be 
effective in reducing PTH in hemodialysis patients, with a 
modest but clinically notable incidence of hypercalcemia 
in 15% of assessments during treatment,54 while more 
recently a minimal increase in Ca and P levels was reported 
among patients receiving paricalcitol55 VDRAs are largely 
used to treat SHPT in dialysis patients. Improved survival 
among ESRD patients receiving VDRA was inconsistently 
reported in observational studies.56–58 Similarly, observational 
data showed heterogeneous results about the superiority 
of paricalcitol against nonselective VDRA in improving 
survival.59 Although selective VDRAs have been purported 
to limit calcitriol administration in CKD patients at higher 
cardiovascular risk,60 it must be noted that the impact of 
different VDRA on hard end points has never been tested in 
head-to-head RCTs. Due to the widespread genomic effect 
elicited by VDR activation, vitamin D is receiving growing 
interest for other targets than SHPT such as proteinuria,61,62 
left ventricular hypertrophy (LVH),16,63 and anemia.64,65 Thus, 
vitamin D represents a culprit of medical therapy for CKD-
MBD. However, further studies are advocated to shed light on 
the many unresolved issues of this multifaceted therapy.66
Parathyroidectomy
Advances in the pharmacological treatment of SHPT often 
obviate parathyroidectomy; however, some researchers have 
reported that parathyroidectomy may be more cost-effective 
than cinacalcet in some patients with ESRD and uncontrolled 
SHPT.67 Successful parathyroidectomy can yield a dramatic 
reduction in PTH level and clinical symptoms.68 Dialysis 
patients undergoing parathyroidectomy have an increased 
risk of cardiopulmonary complications and mortality com-
pared to patients not on dialysis. The risks of parathyroidec-
tomy in dialysis patients are likely similar to other commonly 
performed procedures for dialysis patients. However, a 
retrospective review of dialysis patients with severe and 
unresponsive SHPT indicated that parathyroidectomy did not 
improve cardiovascular outcomes compared with standard 
medical treatment.69 In some instances, SHPT may continue 
Table 2 Stages of chronic kidney disease
Stage Definition GFR (mL/min/1.73 m2)
1 Kidney damage and normal 
or elevated GFR
$90
2 Kidney damage and mild 
reduction in GFR
60–89
3 Moderate reduction in GFR 30–59
4 Severe reduction in GFR 15–29
5 Kidney failure ,15 (or dialysis)
Note: Data from Block et al.30
Abbreviation: GFR, glomerular filtration rate.
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after parathyroidectomy because of incomplete resection or 
because of ongoing PTH secretion from autotransplanted 
parathyroid tissue.11
Current research goals
As of November 30, 2016, 207 studies evaluating sSHPT 
were reported on ClinicalTrials.gov; 137, 26, and 34 studies 
are completed, open, or active but not recruiting patients, 
respectively. Of these 32 are observational and 175 interven-
tional (14 on phase 1, 32 on phase 2, 40 on phase 3, and 55 on 
phase 4; 34 not defined).70,71 The largest proportion of these 
trials were for agents that modulate the activity of the CaSR 
(65 trials related to cinacalcet and 15 trials related to the new 
peptide CaSR agonist etelcalcetide [AMG 416]) or activate 
the VDR (paricalcitol, 94 trials). These findings reflect cur-
rent interest in therapies that target pathways known to be 
involved in the development and progression of SHPT74. 
Etelcalcetide (AMG 416) is a new long-acting peptide cal-
cimimetic agent composed of a linear chain of seven amino 
acids.72 It binds directly to CaSRs, inhibiting the production 
and the secretion of PTH by the parathyroid.73 This activity is 
due to the formation of a disulfide bridge between D-cysteine 
of etelcalcetide molecule and L-cysteine of the CaSRs, result-
ing in a rapid activation of the receptors.74
Several papers have been published in the last 2 years 
about pharmacological properties of etelcalcetide focusing 
on pharmacokinetics, biotransformation, and excretion of the 
drug in animal models2 and in CKD patients on hemodialysis 
treatment.75–77
In rats model with intact kidneys after intravenous dose, 
the drug is rapidly distributed to the tissues, and the renal 
elimination is the major removal pathway, while in binephre-
ctomized rats the nonrenal elimination is only 1.2%.74 Etelcal-
cetide in whole blood is biotransformed by disulfide exchange 
to mainly form a covalent serum albumin peptide conjugate 
(SAPC). The biotransformation process in the human blood is 
reversible, but the rate of SAPC formation from etelcalcetide 
is faster than the inverse process. The preformation of SAPC 
also decreases the clearance rate during hemodialysis.75 When 
etelcalcetide was administered intravenously to CKD patients 
on hemodialysis, the treatment itself was the predominant 
clearance and elimination route, with a 60% of the adminis-
tered dose recovered in the dialysate.72,75 As a result of these 
observations, it was stated that etelcalcetide should be admin-
istered after the hemodialysis session to avoid elimination 
of a substantial fraction of the delivered dose.78 The efficacy 
of etelcalcetide was tested in several studies comparing the 
new molecule with placebo or cinacalcet in CKD patients 
suffering from SHPT on dialysis. In 340 patients receiving 
etelcalcetide versus 343 treated with oral cinacalcet, etelcal-
cetide reduced PTH value 50% more than cinacalcet.9,79,80 In 
another study, etelcalcetide administered thrice a week for 
as long as 26 weeks in 509 patients with moderate-to-severe 
SHPT, compared to 514 treated with placebo, resulted in a 
significantly greater reduction in PTH and FGF-23 values 
(70% versus 30% in placebo group), as well as an improve-
ment in other markers of mineral metabolism.81,82 In a ran-
domized double-blind placebo-controlled trial, patients, dived 
into three cohorts, received etelcalcetide 5 mg or placebo for 
2 weeks (cohort 1), or etelcalcetide 5 mg or 10 mg or placebo 
for 4 weeks (cohorts 2 and 3). The mean percentage change 
from baseline PTH levels was -49% with etelcalcetide 
versus +29% with placebo in cohort 2 (etelcalcetide 10 mg), 
while in cohort 3 (etelcalcetide 5 mg) the percentage change 
was -33% versus +2%. Percentage of patients reaching a PTH 
value reduction of $30% was 76% in etelcalcetide 10 mg 
cohort versus 10% in placebo (P,0.0001). In the cohort with 
etelcalcetide 5 mg, the percentage was smaller (54% versus 
15%). The number of patients achieving at the end of the study 
protocol a PTH value of #300 pg/mL were 67% and 46% in 
etelcalcetide arm 10 and 5 mg, respectively.77,83 According to 
findings from this trial, there was a dose-dependent reduction 
in PTH values and a corresponding effect on the bone forma-
tion (bone-specific alkaline phosphatase) and bone resorption 
(tartrate-resistant acid phosphatase 5b) markers.84 The safety 
profile of etelcalcetide has been studied relative to a specific 
patient population (CKD patients on hemodialysis therapy) 
for whom the drug is intended. During phase 2 and phase 3 
clinical studies, a total of 1,655 subjects received at least 1 
dose of etelcalcetide, and 499 of them received etelcalcetide 
for over 1 year. The most common AE within the placebo-
controlled studies was asymptomatic blood calcium reduction 
(63.8% etelcalcetide; 10.1% placebo).76,85,86 A similar pattern 
was observed in the active-controlled study and consistent 
with the placebo-controlled studies. For the most frequently 
reported AEs, asymptomatic blood calcium reduction (68.9% 
etelcalcetide; 59.8% cinacalcet) was the most important 
adverse effect, while gastrointestinal symptoms were preva-
lent in cinacalcet-treated patients compared to etelcalcetide 
(Table 1). Based on the Kaplan–Meier estimate, the median 
of the first occurrence of hypocalcemic event was 9.6 weeks 
in the placebo-controlled study and 9.6 weeks in active con-
trolled study in the arm of etelcalcetide.87,88
With regard to the incidence of serious AEs, these 
were less frequent (21.4%) in patients with a PTH 
value of .1,000 pg/mL at the screening compared with 
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subjects with PTH .600 #1,000 pg/mL (26.2%) or ,600 
pg/mL (28.2%). A similar behavior has been observed with 
respect to age, with a lower incidence of events related to 
serum calcium reduction (56.5%) in subjects aged $65 years 
compared to ,65 years (67.8%).88 In the pooled placebo-
controlled trials, a QT prolongation (500 ms) secondary to 
hypocalcemia was observed in 4.8% of etelcalcetide and 
1.9% of placebo subjects. For this reason, close monitoring 
of calcium levels is necessary in patients with a previous risk 
factor such as congenital long QT syndrome, previous history 
of QT prolongation, family history of long QT syndrome, or 
sudden cardiac death and other conditions that predispose to 
QT prolongation.88
Considering the overall safety profile of using etelcal-
cetide, we can see that the reported AEs are related to the 
mechanism of action of calcimimetic drugs and are somewhat 
similar to cinacalcet. The most important risk for etelcalcetide 
is hypocalcemia and other events that can occur secondary to 
reductions in serum calcium (ie, QTc prolongation, ventricu-
lar arrhythmia, convulsions, and worsening heart failure). 
These adverse effects, specially hypocalcemia and reduced 
calcium levels, occurred slightly more than with cinacalcet, 
possibly due to a more potent effect of etelcalcetide. However 
in dialysis patients, attending a dialysis unit thrice a week, 
regular monitoring of these parameters will be enough to 
prevent serious AEs. Despite bypassing the gastrointestinal 
tract, owing to intravenous administration, etelcalcetide only 
partially reduced gastrointestinal adverse effects (nausea 
and diarrhea) (Table 3) seen with cinacalcet use, support-
ing evidence that these effects are possibly related to a 
systemic action rather than a local one, mediated by CaSRs 
activation.89 Etelcalcetide intravenous administration at the 
end of the dialysis session, on the contrary, would ameliorate 
substantially the adherence to the SHPT treatment by the 
patients, also reducing the burden of pills of drug therapy. 
On the other hand, the superiority of etelcalcetide versus 
cinacalcet in reducing the levels of sPTH can offer a viable 
chance to demonstrate the role of PTH on the cardiovascular 
risk of patients on dialysis.89,90 The possibility of normalizing, 
with the new available drugs, mineral metabolism in uremic 
patients on dialysis may reduce bias related to the problem 
of therapeutic compliance in RCTs and help to clarify the 
effect of biochemical normalization on patients’ survival, 
even if it will be necessary to clearly identify the patients to 
whom this therapy should be offered, and this is also related 
to the economic capacity of health systems in the various 
countries.91,92 The EMA Assessment Report (Procedure No 
EMEA/H/C/003995/0000) related to “Parsabiv” (Amgen 
Inc, Thousand Oaks, CA, USA) (etelcalcetide), after care-
ful benefit–risk assessment, argues that overall, the benefits 
of etelcalcetide in the treatment of secondary HPT in CKD 
patients are considered to outweigh the risks, recommending 
accurate controls of safety in the postmarketing period.87
Scientific rationale
Vitamin D analogs, such as paricalcitol, selectively target the 
VDR, lowering PTH levels.2 However, clinical data reveal 
that paricalcitol treatment can be associated with elevation in 
serum calcium and phosphorus, and a significant minority of 
patients treated with paricalcitol experience hypercalcemia.16 
Calcimimetics, such as cinacalcet, lower PTH levels and 
reduce serum calcium and phosphorus.15,21,22,30 However, 
cinacalcet is administered orally and has been associated 
with gastrointestinal AEs in approximately 30% of patients 
and with hypocalcemia in 7%.21 In addition, poor adherence 
has been observed among dialysis patients self-administering 
oral cinacalcet.93 Consequently, there has been interest in 
the development of novel CaSR agonists with improved 
tolerability and vitamin D derivatives with reduced calcemic 
actions to further advance the treatment of SHPT.
Table 3 incidence (%) of most frequent adverse drug reactions
Most frequent 
adverse events
Placebo-controlled studies Cinacalcet-controlled studies
Placebo n=513 Etelcalcetide n=503 Cinacalcet n=341 Etelcalcetide n=338
Diarrhea 8.6 10.7 10.3 6.2
Nausea 6.2 10.7 22.6 18.3
vomiting 5.1 8.9 13.8 13.3
Calcium reduction 10.1 63.8 59.8 68.9
Hypocalcemiaa 0.2 7.0 2.3 5.0
Hyperkalemia 3.1 4.4 5.3 3.8
Muscle spasms 6.6 11.5 5.9 6.5
Paraesthesia 1.2 6.2 2.6 3.3
Hypotension – – 2.9 6.8
Note: aHypocalcemia definition: symptomatic reduction in serum corrected calcium ,8.3 mg/dL.
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Conclusion
The pharmacological management of SHPT has progressed 
in recent years. The introduction of targeted therapies, such as 
selective VDR and CaSR modulators, offers an increased oppor-
tunity to adequately control elevated PTH, especially in patients 
with CKD receiving dialysis. Emerging therapies for SHPT, 
such as etelcalcetide (AMG 416) administered intravenously, 
may promote patient adherence, simplify treatment, and, in turn, 
improve the likelihood of achieving treatment goals. However, 
an open question remains as to whether emerging treatments 
for SHPT will reduce the risk of clinical end points such as car-
diovascular morbidity and mortality. If emerging therapies for 
SHPT can reduce PTH, restore mineral homeostasis, promote 
adherence, and reduce the risk of troublesome side effects, they 
may provide the prerequisite features for improving long-term 
outcomes in patients with SHPT receiving dialysis.
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